Evidence map›Paper›PMID 23181936›Full record

ArticleBiochemistry2012

Mapping inhibitor binding modes on an active cysteine protease via nuclear magnetic resonance spectroscopy.

Gregory M Lee, Eaman Balouch, David H Goetz, Ana Lazic, James H McKerrow, Charles S Craik

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gregory M LeeDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158-2280, USA.
Eaman Balouch
David H Goetz
Ana Lazic
James H McKerrow
Charles S Craik
University of California, San Francisco · USUniversity of California, Berkeley · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2007 to 2018
$48.8M
X-RAY CRYSTALLOGRAPHYP01AI035707 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SALI, ANDREJ · 1995 to 2008
$7.8M
RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
K777 for treatment of Chagas Disease: IND-enabling Studies and IND SubmissionR01AI090592 · NIAID · DRUGS FOR NEGLECTED DISEASES INITIATIVE · PI DON, ROBERT · 2010 to 2012
$1.2M
Allosteric Inhibition of a Family of Proteolytic EnzymesR01GM104659 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2013 to 2016
$1.2M
NCI NIH HHS P30 CA082103NCI NIH HHS P30-CA-82103-13NIAID NIH HHS P01 AI035707NIAID NIH HHS R01 AI090592NIAID NIH HHS R01-AI090592NIGMS NIH HHS P50 GM082250NIGMS NIH HHS P50-GM-082250NIGMS NIH HHS R01 GM104659NIGMS NIH HHS T32 GM064337PHS HHS P01-A135707
6 · The paper itself

Abstract

Cruzain is a member of the papain/cathepsin L family of cysteine proteases, and the major cysteine protease of the protozoan Trypanosoma cruzi, the causative agent of Chagas disease. We report an autoinduction methodology that provides soluble cruzain in high yields (>30 mg/L in minimal medium). These increased yields provide sufficient quantities of active enzyme for use in nuclear magnetic resonance (NMR)-based ligand mapping. Using circular dichroism and NMR spectroscopy, we also examined the solution-state structural dynamics of the enzyme in complex with a covalently bound vinyl sulfone inhibitor (K777). We report the backbone amide and side chain carbon chemical shift assignments of cruzain in complex with K777. These resonance assignments were used to identify and map residues located in the substrate binding pocket, including the catalytic Cys25 and His162. Selective [(15)N]Cys, [(15)N]His, and [(13)C]Met labeling was performed to quickly assess cruzain-ligand interactions for a set of eight low-molecular weight compounds exhibiting micromolar binding or inhibition. Chemical shift perturbation mapping verified that six of the eight compounds bind to cruzain at the active site. Three different binding modes were delineated for the compounds, namely, covalent, noncovalent, and noninteracting. These results provide examples of how NMR spectroscopy can be used to screen compounds for fast evaluation of enzyme-inhibitor interactions to facilitate lead compound identification and subsequent structural studies.

Indexed as

Amino Acid SequenceCatalytic DomainCysteine EndopeptidasesCysteine Proteinase InhibitorsDipeptidesNuclear Magnetic Resonance, BiomolecularPhenylalaninePiperazinesProtozoan ProteinsTosyl CompoundsTrypanosoma cruziVinyl Compoundscruzain, Trypanosoma cruziCysteine EndopeptidasesCysteine Proteinase InhibitorsDipeptidesN-pip-phenylalanine-homophenylalanine-vinyl sulfone phenylPhenylalaninePiperazinesProtozoan ProteinsTosyl CompoundsVinyl Compounds

Identifiers

PMID23181936
PMCPMC3566641
OpenAlexW2111725364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.